These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12720152)

  • 1. Potential new therapeutics for Waldenstrom's macroglobulinemia.
    Zeldis JB; Schafer PH; Bennett BL; Mercurio F; Stirling DI
    Semin Oncol; 2003 Apr; 30(2):275-81. PubMed ID: 12720152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.
    Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PP; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1222-32. PubMed ID: 12649301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
    Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
    Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thalidomide: mechanisms of action and new insights in hematology].
    Leleu X; Micol JB; Guieze R; Berthon C; Kuhnovsky F; Terriou L; Moreau AS; Yakoub-Agha I; Bauters F; Facon T
    Rev Med Interne; 2005 Feb; 26(2):119-27. PubMed ID: 15710258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel biologically based therapies for Waldenstrom's macroglobulinemia.
    Mitsiades CS; Mitsiades N; Richardson PG; Treon SP; Anderson KC
    Semin Oncol; 2003 Apr; 30(2):309-12. PubMed ID: 12720159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
    Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
    Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Properties of thalidomide and its analogues: implications for anticancer therapy.
    Teo SK
    AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMiDs: a novel class of immunomodulators.
    Knight R
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
    Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
    Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
    Anderson KC
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor-gamma-independent mechanism.
    Grau R; Iñiguez MA; Fresno M
    Cancer Res; 2004 Aug; 64(15):5162-71. PubMed ID: 15289320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues.
    Prehn JL; Landers C; Muller GW; Man HW; Stirling DI; Targan SR
    J Clin Immunol; 2001 Sep; 21(5):357-64. PubMed ID: 11720008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.
    Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG
    Br J Cancer; 2002 Nov; 87(10):1166-72. PubMed ID: 12402158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in the treatment of Waldenström's macroglobulinemia.
    Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
    Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
    Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
    Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone.
    Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N
    Semin Oncol; 2003 Apr; 30(2):265-9. PubMed ID: 12720150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-1 and TNF induction of matrix metalloproteinase-3 by c-Jun N-terminal kinase in trabecular meshwork.
    Hosseini M; Rose AY; Song K; Bohan C; Alexander JP; Kelley MJ; Acott TS
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1469-76. PubMed ID: 16565381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.
    Payvandi F; Wu L; Naziruddin SD; Haley M; Parton A; Schafer PH; Chen RS; Muller GW; Hughes CC; Stirling DI
    J Interferon Cytokine Res; 2005 Oct; 25(10):604-16. PubMed ID: 16241859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A safety profile of medications used to treat Waldenström's macroglobulinemia.
    García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
    Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
    Roccaro AM; Leleu X; Sacco A; Moreau AS; Hatjiharissi E; Jia X; Xu L; Ciccarelli B; Patterson CJ; Ngo HT; Russo D; Vacca A; Dammacco F; Anderson KC; Ghobrial IM; Treon SP
    Clin Cancer Res; 2008 Mar; 14(6):1849-58. PubMed ID: 18347188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.